1. Home
  2. RCS vs ITOS Comparison

RCS vs ITOS Comparison

Compare RCS & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RCS
  • ITOS
  • Stock Information
  • Founded
  • RCS 1994
  • ITOS 2011
  • Country
  • RCS United States
  • ITOS United States
  • Employees
  • RCS N/A
  • ITOS N/A
  • Industry
  • RCS Investment Managers
  • ITOS Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • RCS Finance
  • ITOS Health Care
  • Exchange
  • RCS Nasdaq
  • ITOS Nasdaq
  • Market Cap
  • RCS N/A
  • ITOS 270.7M
  • IPO Year
  • RCS N/A
  • ITOS 2020
  • Fundamental
  • Price
  • RCS $6.05
  • ITOS $6.70
  • Analyst Decision
  • RCS
  • ITOS Strong Buy
  • Analyst Count
  • RCS 0
  • ITOS 3
  • Target Price
  • RCS N/A
  • ITOS $25.67
  • AVG Volume (30 Days)
  • RCS 141.1K
  • ITOS 553.7K
  • Earning Date
  • RCS 01-01-0001
  • ITOS 04-28-2025
  • Dividend Yield
  • RCS 10.12%
  • ITOS N/A
  • EPS Growth
  • RCS N/A
  • ITOS N/A
  • EPS
  • RCS N/A
  • ITOS N/A
  • Revenue
  • RCS N/A
  • ITOS $35,000,000.00
  • Revenue This Year
  • RCS N/A
  • ITOS N/A
  • Revenue Next Year
  • RCS N/A
  • ITOS $31.74
  • P/E Ratio
  • RCS N/A
  • ITOS N/A
  • Revenue Growth
  • RCS N/A
  • ITOS 177.89
  • 52 Week Low
  • RCS $4.51
  • ITOS $4.80
  • 52 Week High
  • RCS $6.31
  • ITOS $18.75
  • Technical
  • Relative Strength Index (RSI)
  • RCS 63.57
  • ITOS 49.45
  • Support Level
  • RCS $5.25
  • ITOS $6.58
  • Resistance Level
  • RCS $5.90
  • ITOS $7.80
  • Average True Range (ATR)
  • RCS 0.12
  • ITOS 0.51
  • MACD
  • RCS 0.09
  • ITOS -0.03
  • Stochastic Oscillator
  • RCS 96.34
  • ITOS 32.10

About ITOS iTeos Therapeutics Inc.

ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.

Share on Social Networks: